Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Zenas BioPharma (Nasdaq: ZBIO) granted inducement equity awards to newly hired employees under Nasdaq Listing Rule 5635(c)(4). The June 15, 2026 grants include non-qualified stock options for 100,000 shares at a $18.71 exercise price and 78,075 RSUs, all vesting over four years.
Positive
- Inducement grants total 100,000 stock options and 78,075 RSUs for new hires
- Four-year vesting schedules may support employee retention and long-term focus
Negative
- New equity awards create potential dilution of up to 178,075 shares
- Options have a 10-year term, extending potential dilution window for shareholders
News Market Reaction – ZBIO
In the Jun 18 session, ZBIO gained 6.46%, reflecting a notable positive market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 11 | Conference presentation | Positive | +11.5% | Announcement of management presentation at H.C. Wainwright neuro summit. |
| Jun 02 | Phase 3 data | Positive | +1.6% | INDIGO Phase 3 trial in IgG4-RD met primary and key secondary endpoints. |
| May 28 | BLA submission | Positive | +2.6% | BLA filed with FDA for obexelimab in IgG4-RD supported by INDIGO trial. |
| May 19 | Phase 3 update | Positive | +6.5% | Further disclosure of Phase 3 INDIGO results with strong efficacy and safety. |
| May 18 | Inducement grants | Neutral | +6.5% | RSU inducement awards to new hires under 2026 Inducement Plan. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Over the last month, ZBIO often traded higher on positive clinical and regulatory milestones, including obexelimab Phase 3 data and BLA progress, and even reacted positively to a prior inducement grant.
Recent news for ZBIO has centered on obexelimab’s late-stage progress and capital markets activity. On May 28, 2026, the company announced a BLA submission to the FDA for obexelimab in IgG4-RD, supported by Phase 3 INDIGO data, and the stock rose. Phase 3 INDIGO results highlighted significant flare risk reduction and favorable safety, with additional data and presentations around May–June 2026. Alongside this, ZBIO issued inducement RSU grants under its 2026 Inducement Plan and participated in investor conferences, with shares generally responding positively to these updates.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
non-qualified stock options financial
restricted stock units financial
inducement grant financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on June 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 100,000 shares of the Company’s common stock (“Stock Options”) and an aggregate of 78,075 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
The Stock Options have a ten-year term and an exercise price per share of
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a novel, potentially best-in-class, oral, IL-17AA/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.
The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.
Investor and Media Contact:
Argot Partners
Zenas@argotpartners.cocham
